Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Stem Cell Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM), showing >200-fold selectivity against other kinases (APExBIO). It disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis in vitro (Khosrowpour et al. 2025). Y-27632 enhances stem cell viability and facilitates long-term engraftment of myogenic progenitors in preclinical models (Cells 2025, 14, 1150). APExBIO’s A3008 kit provides reliable, high-purity Y-27632 for use in cancer, stem cell, and cytoskeletal studies, with validated protocols for solubility and storage (APExBIO).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that function as central effectors in the Rho/ROCK signaling pathway. They regulate actin cytoskeleton remodeling, cell contractility, and cell cycle progression (INCA-6). Inhibition of ROCK1/2 blocks the assembly of actin stress fibers and focal adhesions, key steps in cell migration and adhesion. ROCK signaling impacts stem cell survival, tissue regeneration, and epithelial barrier function. By targeting ROCK kinases, Y-27632 dihydrochloride enables precise modulation of cytoskeletal dynamics, making it vital in studies of stem cell engraftment, tumor invasion, and tissue morphogenesis (Khosrowpour et al. 2025).

This article extends recent mechanistic summaries (INCA-6), providing updated evidence on stem cell viability and tumor models.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds the catalytic domains of ROCK1 and ROCK2, inhibiting their kinase activity. The compound displays an IC₅₀ of approximately 140 nM for ROCK1 and a K_i of 300 nM for ROCK2 (APExBIO). Selectivity exceeds 200-fold compared to PKC, cAMP-dependent protein kinase, MLCK, and PAK. Inhibition of ROCK prevents Rho-mediated phosphorylation of downstream targets such as myosin light chain (MLC), LIM kinase, and cofilin. This results in reduced actomyosin contractility, loss of stress fibers, and impaired cytokinesis. In stem cells, Y-27632 increases survival by preventing detachment-induced apoptosis (anoikis). In cancer models, ROCK inhibition suppresses cell migration, invasion, and metastasis (CHIR-090).

This article clarifies the target selectivity and cellular outcomes compared to broad overviews in (CHIR-090).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of approximately 140 nM and ROCK2 with a K_i of 300 nM under cell-free conditions (APExBIO).
• Y-27632 exhibits >200-fold selectivity over PKC, cAMP-dependent protein kinase, MLCK, and PAK (APExBIO).
• In vitro, Y-27632 reduces prostatic smooth muscle cell proliferation in a dose-dependent manner (10–100 μM, 24–72 h) (Khosrowpour et al. 2025).
• In vivo, Y-27632 diminishes tumor invasion and metastasis in mouse models of cancer (Cells 2025, 14, 1150).
• Y-27632 enables cryopreserved human iPSC-derived myogenic progenitors to maintain engraftment potential after transplantation (Khosrowpour et al. 2025, Fig. 3).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C (APExBIO).
• Long-term solution storage (>1 week) at 4°C leads to potency loss; recommended storage below –20°C as solid (APExBIO).

For advanced 3D organoid and neurodevelopmental disease models, see contrasting protocols in Surface Antigen (focus on 3D culture workflows; this article emphasizes cytoskeleton and stem cell benchmarks).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is primarily used as a selective ROCK1/2 inhibitor in cell and tissue models. Its applications include:

• Enhancing survival and expansion of human pluripotent stem cells (hPSCs) and myogenic progenitors.
• Studying Rho/ROCK signaling in cytoskeletal regulation, cell migration, and adhesion.
• Inhibiting cytokinesis and modulating cell cycle progression.
• Suppressing tumor cell invasion and metastasis in cancer models.
• Improving viability during stem cell dissociation and passage (Khosrowpour et al. 2025).

Common Pitfalls or Misconceptions

• Y-27632 is not a broad-spectrum kinase inhibitor; it does not significantly inhibit PKC, MLCK, or PAK at working concentrations.
• Long-term storage of Y-27632 solutions at 4°C results in potency loss; always store as a solid below –20°C.
• In vivo effects are context-dependent: not all tumor models respond equally to ROCK inhibition.
• Y-27632 does not reverse established fibrosis; its primary effect is on cytoskeletal remodeling and cell viability.
• ROCK inhibition may affect multiple cell types in mixed cultures, complicating attribution of specific phenotypes.

For gut–brain axis and neurodegeneration studies, see L3400.com (this article focuses on cytoskeletal and stem cell contexts).

Workflow Integration & Parameters

Y-27632 dihydrochloride (A3008, APExBIO) is supplied as a solid and should be stored desiccated at 4°C or below. For solution preparation:

• Dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water.
• Gently warm (37°C) or use an ultrasonic bath to facilitate dissolution.
• Filter-sterilize prior to cell culture use (0.22 μm filter recommended).
• Store stock solutions below –20°C for up to several months; avoid repeated freeze-thaw cycles.
• Working concentrations typically range from 5–20 μM for stem cell and cytoskeletal assays.

For detailed practical handling and troubleshooting, see the Y-27632 dihydrochloride product page or advanced application notes (DYNGO-4A for neurodevelopmental models; this article provides broader mechanistic context).

Conclusion & Outlook

Y-27632 dihydrochloride is a gold-standard, selective ROCK1/2 inhibitor for dissecting Rho/ROCK signaling in cytoskeletal, stem cell, and cancer research. Its high selectivity and robust solubility profile enable reproducible results in diverse in vitro and in vivo models. By enhancing stem cell viability and suppressing tumor invasion, Y-27632 supports both basic and translational research. Future work will further refine ROCK-targeted strategies for regenerative medicine and cancer therapy. For validated reagents and protocols, APExBIO provides the A3008 kit with detailed technical support.